NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice

Psychopharmacology

Volumn 223, Issue 3, 2012, Pages 345-355

  Salehi Sadaghiani, Mohammad ^a,b,c   Javadi Paydar, Mehrak ^a,b,c   Gharedaghi, Mohammad Hadi ^a,b,c   Zandieh, Ali ^a,b,c   Heydarpour, Pouria ^a,b,c   Yousefzadeh fard, Yashar ^a,b,c   Dehpour, Ahmad Reza ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Depression; Forced swimming test; Mice; N methyl D aspartate (NMDA) receptor; Pioglitazone; PPAR ; Thiazolidinedione

Indexed keywords

DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FORCED SWIMMING TEST; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; MICE; MICE, INBRED STRAINS; MOTOR ACTIVITY; RECEPTORS, N-METHYL-D-ASPARTATE; SWIMMING; THIAZOLIDINEDIONES;

EID: 84866739930     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2722-0     Document Type: Article

References (66)

1. Aihara M, Ida I, Yuuki N, Oshima A, Kumano H, Takahashi K, Fukuda M, Oriuchi N, Endo K, Matsuda H (2007) HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions. Psychiatry Res Neuroimaging 155:245-256
2. Allahtavakoli M, Shabanzadeh A, Roohbakhsh A, Pourshanazari A (2007) Combination therapy of rosiglitazone, a peroxisome proliferator activated receptor ligand, and NMDA receptor antagonist (MK 801) on experimental embolic stroke in rats. Basic Clin Pharmacol Toxicol 101:309-314
3. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ (2001) The prevalence of comorbid depression in adults with diabetes. Diabetes Care 24:1069
4. Aoun P, Simpkins JW, Agarwal N (2003) Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells. Investig Ophthalmol Vis Sci 44:2999
5. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan F, Williams B, Crombie I (2005) Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-Analysis. Ann Fam Med 3:449-456
6. Baxter AJ, Charlson FJ, Somerville AJ, Whiteford HA (2011) Mental disorders as risk factors: Assessing the evidence for the global burden of disease study. BMC Med 9:134
7. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354
8. Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M (2006) PPAR: A new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34:1341-1346
9. Brasier AR (2006) The NF-kappaB regulatory network. Cardiovasc Toxicol 6:111-130
10. Brocardo PS, Budni J, Lobato KR, Santos ARS, Rodrigues ALS (2009) Evidence for the involvement of the opioid system in the antidepressant-like effect of folic acid in the mouse forced swimming test. Behav Brain Res 200:122-127
11. Budni J, Lobato KR, Binfare RW, Freitas AE, Costa AP, Saavedra MD, Leal RB, Lopez MG, Rodrigues AL (2011) Involvement of PI3K, GSK-3beta and PPARgamma in the antidepressant-like effect of folic acid in the forced swimming test in mice. J Psychopharmacol. doi:10.1177/0269881111424456
12. Cho SI, Park UJ, Chung JM, Gwag BJ (2010) Neu 2000, an NR2Bselective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect 23:549-556
13. Cimini A, Benedetti E, Cristiano L, Sebastiani P, D'amico M, D'angelo B, Di Loreto S (2005) Expression of peroxisome proliferatoractivated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 130:325-337
14. Consoni FT, Vital MABF, Andreatini R (2006) Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. Eur Neuropsychopharmacol 16:451-458
15. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: Recent developments and future needs. Trends Pharmacol Sci 23:238-245
16. De Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ (2001) Association of depression and diabetes complications: A meta-Analysis. Psychosom Med 63:619
17. Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 88:494-501
18. Eissa Ahmed AA, Al-Rasheed NM (2009) Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol 20:635-642
19. Esplugues JV (2002) NO as a signalling molecule in the nervous system. Br J Pharmacol 135:1079-1095
20. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, Landreth GE, Pershadsingh HA, Weinberg G, Heneka MT (2002) Peroxisome proliferator-Activated receptorgamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 51:694-702
21. Gardoni F, Ghiglieri V, Luca M, Calabresi P (2010) Assemblies of glutamate receptor subunits with post-synaptic density proteins and their alterations in Parkinson's disease. Prog Brain Res 183:169-182
22. Geldmacher DS, Fritsch T, McClendon MJ, Landreth G (2011) A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 68:45-50
23. Ghasemi M, Montaser-Kouhsari L, Shafaroodi H, Nezami BG, Ebrahimi F, Dehpour AR (2009) NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology (Berl) 206:325-333
24. Ghasemi M, Raza M, Dehpour AR (2010) NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J Psychopharmacol 24:585-594
25. Gonzalez O, Berry J, McKnight-Eily L, Strine T, Edwards V, Lu H, Croft J (2010) Current depression among adults: United States, 2006 and 2008. Morb Mortal Wkly Rev 59:1229-1235
26. Hara MR, Snyder SH (2007) Cell signaling and neuronal death. Annu Rev Pharmacol Toxicol 47:117-141
27. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, Zarate CA Jr (2011) Rapid decrease in depressive symptoms with an N-methyl-D-Aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 35:1155-1159
28. Ji-Rong Y, Bi-Rong D, Chang-Quan H, Zhen-Chan L, Hong-Mei W, Yan-Ling Z, Mattis TA (2009) Pro12Ala polymorphism in PPAR [gamma] 2 associated with depression in Chinese nonagenarians/ centenarians. Arch Med Res 40:411-415
29. Kantrowitz JT, Javitt DC (2010) Thinking glutamatergically: Changing concepts of schizophrenia based upon changing neurochemical models. Clin Schizophr Relat Psychoses 4:189-200
30. Katon W, Fan MY, Unützer J, Taylor J, Pincus H, Schoenbaum M (2008) Depression and diabetes: A potentially lethal combination. J Gen Intern Med 23:1571-1575
31. Kemp DE, Ismail-Beigi F, Calabrese JR (2009) Antidepressant response associated with pioglitazone: Support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry 166:619
32. Kemp DE, Ismail-Beigi F, Ganocy SJ, Conroy C, Gao K, Obral S, Fein E, Findling RL, Calabrese JR (2011) Use of insulin sensitizers for the treatment of major depressive disorder: A pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord 136:1164-1173
33. Kessler RC, Merikangas KR, Wang PS (2007) Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol 3:137-158
34. Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF (2005) Peroxisome proliferator-Activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 191:331-336
35. Konarski JZ, McIntyre RS, Kennedy SH, Rafi Tari S, Soczynska JK, Ketter TA (2008) Volumetric neuroimaging investigations in mood disorders: Bipolar disorder versus major depressive disorder. Bipolar Disord 10:1-37
36. Kummer MP, Heneka MT (2008) PPARs in Alzheimer's disease. PPAR Res 2008:403896
37. Laursen SE, Belknap JK (1986) Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 16:355-357
38. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-Activated receptor gamma (PPAR gamma). J Biol Chem 270:12953-12956
39. Mantovani M, Pertile R, Calixto JB, Santos AR, Rodrigues AL (2003) Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: Evidence for involvement of N-methyl-D-Aspartate receptors and the L-Arginine-nitric oxide pathway. Neurosci Lett 343:1-4
40. Metzler M (2011) Mutations in NMDA receptors influence neurodevelopmental disorders causing epilepsy and intellectual disability. Clin Genet 79:219-220
41. Milnerwood AJ, Raymond LA (2010) Early synaptic pathophysiology in neurodegeneration: Insights from Huntington's disease. Trends Neurosci 33:513-523
42. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera- Lopez JI, Jaramillo-Jaimes MT (2008) Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 32:380-386
43. Moncada S, Palmer R, Higgs E (1991) Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43:109-142
44. Munhoz CD, Garcia-Bueno B, Madrigal JL, Lepsch LB, Scavone C, Leza JC (2008) Stress-induced neuroinflammation: Mechanisms and new pharmacological targets. Braz J Med Biol Res 41:1037-1046
45. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2008) Management of hyperglycaemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia 51:8-11
46. Paul IA, Skolnick P (2003) Glutamate and depression: Clinical and preclinical studies. Ann N Y Acad Sci 1003:250-272
47. Pancani T, Phelps JT, Searcy JL, Kilgore MW, Chen KC, Porter NM, Thibault O (2009) Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J Neurochem 109:1800-1811
48. Pereira MP, Hurtado O, Cardenas A, Bosca L, Castillo J, Davalos A, Vivancos J, Serena J, Lorenzo P, Lizasoain I, Moro MA (2006) Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 26:218-229
49. Poleszak E, Wlaz P, Kedzierska E, Nieoczym D, Wrobel A, Fidecka S, Pilc A, Nowak G (2007) NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav 88:158-164
50. Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327-336
51. Racke MK, Gocke AR, Muir M, Diab A, Drew PD, Lovett-Racke AE (2006) Nuclear receptors and autoimmune disease: The potential of PPAR agonists to treat multiple sclerosis. J Nutr 136:700-703
52. Riederer P, Bartl J, Laux G, Grünblatt E (2011) Diabetes type II: A risk factor for depression-Parkinson-Alzheimer? Neurotox Res 19:253-265
53. Rosa AO, Lin J, Calixto JB, Santos ARS, Rodrigues ALS (2003) Involvement of NMDA receptors and L-Arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res 144:87-93
54. Rosa AO, Kaster MP, Binfare RW, Morales S, Martin-Aparicio E, Navarro-Rico ML, Martinez A, Medina M, Garcia AG, Lopez MG, Rodrigues AL (2008) Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatry 32:1549-1556
55. Sadaghiani MS, Javadi-Paydar M, Gharedaghi MH, Fard YY, Dehpour AR (2011) Antidepressant-like effect of pioglitazone in the forced swimming test in mice: The role of PPAR-gamma receptor and nitric oxide pathway. Behav Brain Res 224:336-343
56. Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR (2009) PPAR gamma mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur J Neurosci 29:954-963
57. Schutz B, Reimann J, Dumitrescu-Ozimek L, Kappes-Horn K, Landreth GE, Schurmann B, Zimmer A, Heneka MT (2005) The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci 25:7805-7812
58. Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30:563-569
59. Tokita K, Yamaji T, Hashimoto K (2011) Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185:1-10
60. Wilken R, Veena MS, Wang MB, Srivatsan ES (2011) Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10:12
61. Yaffe K, Kanaya A, Lindquist K, Hsueh W, Cummings S, Beamer B, Newman A, Rosano C, Li R, Harris T (2008) PPAR-[gamma] Pro12Ala genotype and risk of cognitive decline in elders. Neurobiol Aging 29:78-83
62. Yki-Järvinen H (2004) Thiazolidinediones. N Engl J Med 351:1106- 1118
63. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-Aspartate antagonist in treatment-resistantmajor depression. Arch Gen Psychiatry 63:856-864
64. Zekry D, Gold G (2010) Management of mixed dementia. Drugs Aging 27:715-728
65. Zhang F, Sowers JR, Ram JL, Standley PR, Peuler JD (1994) Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24:170-175
66. Zhao X, Ou Z, Grotta JC, Waxham N, Aronowski J (2006) Peroxisome-proliferator-Activated receptor-gamma (PPAR [gamma]) activation protects neurons from NMDA excitotoxicity. Brain Res 1073:460-469